PVLA
Palvella Therapeutics, Inc.
There isn't enough reported data to score PVLA yet.
PVLA Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
PVLA's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
PVLA PE Valuation
PVLA has no meaningful PE right now: it lost money over the past year.
PVLA Forward outlook
There aren't enough analyst estimates for PVLA to show an outlook.
PVLA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$12.97 | +$14.97 |
| Q2 2024 | -$19.58 | +$9.96 |
| Q1 2024 | -$12.82 | +$31.92 |
| Q4 2023 | -$23.27 | +$12.67 |
| Q3 2023 | -$27.94 | +$11.26 |
| Q2 2023 | -$29.54 | +$18.46 |
| Q1 2023 | -$44.74 | +$12.06 |
| Q4 2022 | -$35.94 | +$20.86 |
PVLA is still losing money, but far less than before: $5.50 per share over the past year, against $67.20 at its worst in mid-2021.
PVLA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2024 | $53K | -97% |
| Q4 2023 | $1.3M | -78% |
| Q3 2023 | $19.5M | +264% |
| Q2 2023 | $20.1M | +442% |
| Q1 2023 | $1.9M | -82% |
| Q4 2022 | $5.8M | -31% |
| Q3 2022 | $5.4M | +32% |
| Q2 2022 | $3.7M | +13% |
PVLA's revenue has slid since its 2023 peak: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2024 | -10006% | -9205 points |
| Q4 2023 | -347% | -150 points |
| Q3 2023 | -60% | +166 points |
| Q2 2023 | 10% | +344 points |
| Q1 2023 | -801% | -733 points |
| Q4 2022 | -197% | -67 points |
| Q3 2022 | -227% | +242 points |
| Q2 2022 | -333% | +177 points |
PVLA's operating margin was −10006% last quarter, down 9204 points from the same quarter a year ago, near the bottom of its range since 2019.
PVLA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$14.4M | -$6.6M |
| Q2 2026 | -$12.8M | -$7.4M |
| Q1 2026 | -$10.9M | -$4.1M |
| Q4 2025 | -$4.9M | -$2.4M |
| Q3 2025 | -$7.9M | -5496% |
| Q2 2025 | -$5.4M | -$4M |
| Q1 2025 | -$6.8M | +$228K |
| Q4 2024 | -$2.5M | +$17.1M |
PVLA has burned cash in almost every quarter: −$43M over the past year, against −$23M the year before.
PVLA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +175K shares |
| 1 year | +31% | +3.5M shares |
| 3 years | +1460% | +13.6M shares |
| 5 years | +1965% | +13.8M shares |
| Available history | +2196% | +13.9M shares |
PVLA has 15M diluted shares, up 31% from a year ago.
PVLA Net Leverage
PVLA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
PVLA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.2 | Neutral |
| Stochastic | 73.5 | Neutral |
PVLA's weekly RSI is 55 (neutral) and its Stochastic is 73 (neutral).
PVLA PE vs Healthcare Sector
PVLA has no meaningful PE right now: it lost money over the past year.
PVLA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $141.3 | 8.4% above |
| 20 week MA | $146.0 | 4.9% above |
| 50 week MA | $124.4 | 23% above |
| 100 week MA | $81.0 | 89% above |
| 200 week MA | $56.7 | 170% above |
PVLA is in an uptrend: it's above all five of its weekly moving averages, and 170% above its 200-week average.
PVLA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $265.6 | $219.2 | -17% |
| 2021 | $219.2 | $293.6 | +34% |
| 2022 | $293.6 | $72.8 | -75% |
| 2023 | $72.8 | $14.6 | -80% |
| 2024 | $14.6 | $12.0 | -18% |
| 2025 | $12.0 | $103.4 | +761% |
| 2026 YTD | $103.4 | $153.2 | +48% |
PVLA's yearly returns have swung widely, from +761% in 2025 to −80% in 2023. It's up 48% so far in 2026.